Benzinga's Microcap Movers for Tuesday January 24, 2012

Below are highlights from Benzinga's daily coverage of microcap securities making big moves:

Shares of BioLineRx

, the Israel-based clinical-stage biopharmaceutical development company, rose 68% Tuesday on 2,093 times the average daily volume. BioLineRx announced Tuesday it has signed a worldwide, exclusive license agreement with Genoscience, a French company focused on viral disease therapeutics, to develop and commercialize BL-8020, an orally available treatment for Hepatitis C. BL-8020 acts via a unique mechanism of action, by inhibiting Hepatitis C virus-induced autophagy, which differs from the mechanism of currently used anti-HCV agents. BL-8020's safety and efficacy were demonstrated in pre-clinical studies. These studies have shown that BL-8020, when combined with other anti-Hepatitis C virus agents, has a synergistic effect. BL-8020's synergistic effect on other therapies is likely to increase their potency and reduce the numerous adverse effects often associated with these drugs, by enabling utilization of lower dosages. In addition BL-8020 may reduce therapy duration, which is currently up to 48 weeks. The use of two drugs acting by different mechanisms is also likely to be beneficial for patients who have developed resistance to current treatments and is an effective strategy used against other viruses such as HIV. BioLineRx traded as high as $6.87 Tuesday and closed at $5.55.

Shares of Seven Arts Entertainment,

, the Los Angeles, CA independent motion picture production and distribution company, fell 7.5% Tuesday on 6 times the average daily volume. Stock promoter Jonathan Lebed, who is responsible for much of the price rise in Broadvision, mentioned SAPX in an email this morning. Shares rose as high as $0.60 in the pre-market and $0.55 during the regular session. Also, Seven Arts announced Wednesday that it has executed a definitive agreement with David Michery to acquire his music assets. The acquired Michery assets are comprised of recording agreements with several artists, including two completed albums with multi-platinum artist DMX. Seven Arts also announced that "Undisputed," the first of these two completed DMX albums, is scheduled to be released in the United States in the second quarter of 2012 through Fontana Distribution, a division of Universal Music Group. The terms of the acquisition were not disclosed. Seven Arts Entertainment closed at $0.43 Tuesday.

Shares of TearLab

, the San Diego, CA ophthalmic device company, rose 28% Tuesday on 5 times the average daily volume. TearLab announced today that, after reviewing and accepting labeling submitted to it by the Company, the U.S. Food and Drug Administration has now granted Waiver categorization under the Clinical Laboratory Improvement Amendments of 1988 for the TearLab Osmolarity System. TearLab closed at $1.61 Tuesday.